KDR and neoplasm: Regorafenib and cabozantinib (additional kinase inhibitors), and ramucirumab (monoclonal anti-vascular endothelial growth factor receptor-2 [VEGFR-2] antagonist that inhibits tumor angiogenesis) are administered as second-line therapies.